header mobiles

SCIENTIFIC PROGRAM

FINAL SCIENTIFIC PROGRAMME

Thursday, September 7, 2017

16.00-18.00 Pre-meeting Clinical Workshop, including educational videos and interactive case presentations of patients with synucleinopathies
Chairs: Maria Stamelou, Wolfgang Oertel
Presenters: Christos Proukakis, Janice Holton, Stanley Fahn, Leonidas Stefanis, Maria Stamelou, Marianna Bregianni and Christos Koros

18.00-18.15 Short Break

18.15-20.00 Session on PD therapies, past and present
Chairs: Leonidas Stefanis
Introductory Comments: Leonidas Stefanis
18.15-19.00 Update on current therapies for advanced PD, Wolfgang Oertel
19.00-20.00 Inaugural Lecture
50 years of dopamine supplementation therapy in Parkinson’s Disease and related disorders, Stanley Fahn

FIRST DAY
Friday, September 8, 2017

8.30-9.45 Sporadic PD (1)
Chairs: Thomas Gasser, Leonidas Stefanis
GWAS and beyond, Thomas Gasser
Transcriptional and translational control of SNCA, Epaminondas Doxakis
Epigenetic control of SNCA, Mathias Toft
Mosaicism: Could it be involved in SNCA regulation in sporadic PD?, Christos Proukakis
Gene-environment interaction in sporadic PD, Alexis Elbaz

09.45-11.15 Sporadic PD (2)
Chairs: Glenda Halliday, Paolo Calabresi
Neuropathological studies in longitudinally followed cohorts of sporadic PD, Glenda Halliday
CSF Biomarkers in sporadic PD, Paolo Calabresi
Novel assays to assess alpha-synuclein aggregation in synucleinopathies, Alison Green
Peripheral alpha-synuclein Biomarkers: Kuldip Dave
Inflammation in PD: Lessons from animal models and imaging studies, Marina Romero-Ramos
The relationship between Nurr-1 and alpha-synuclein in the aging brain, Demitris Vassilatis

11.15-11.45 ROUND TABLE DISCUSSION ON SPORADIC PD
Chairs: Thomas Gasser and Paolo Calabresi

11.45-12.15 COFFEE BREAK

12.15-13.30 SNCA-dependent genetic synucleinopathies
Chairs: Aglaia Athanasiadou, Leonidas Stefanis
Historical aspects of the Contursi kindred, Paolo Barone
The clinical picture and Biomarker studies in the Greek Contursi kindred, Leonidas Stefanis
Neuropathology of SNCA-dependent genetic synucleinopathies, Janice Holton
What is the pathological function conferred by SNCA mutations?, Tiago Outeiro
iPS-derived neurons for the study of the Contursi kindred, Rebecca Matsas

13.30-14.00 ROUND TABLE DISCUSSION ON SNCA-dependent genetic synucleinopathies

14.00-15.15 LUNCH

15.15-16.30 LRRK2-related synucleinopathies
Chairs: Roy Alcalay, Andy West
Update on LRRK2 genetics, Thomas Gasser
Clinical picture of LRRK2 cohorts, Eduardo Tolosa
CSF biomarkers in LRRK2 cohorts, Omar-el-Agnaf
Towards LRRK2-specific biomarkers, Hardy Rideout
Neurobiology of LRRK2 and its link to alpha-synuclein, Andy West

16.30-17.00 ROUND TABLE DISCUSSION ON LRRK2-related synucleinopathies

17.00-17.30 COFFEE BREAK

17.30-18.30 GBA-related synucleinopathies
Chairs: Michael Schlossmacher, Ellen Sidransky
The genetic link of GBA to PD: Insights into pathogenesis, Ellen Sidransky
Clinical picture and Biomarkers in GBA-associated PD, Roy Alcalay
Insights into GBA-associated PD through the study of iPS-derived neurons, Matthew Gegg
Link of alpha-synuclein to GCase: Insights from experimental models, Pablo Sardi

18.30-19.00 ROUND TABLE DISCUSSION ON GBA-related synucleinopathies

19.00-20.00 KEYNOTE ADDRESS I: The legacy of the Contursi kindred
Chair: Leonidas Stefanis
19.00-19.10 Address by a Greek member of the Contursi kindred
19.10-19.15 Introduction: Thomas Gasser
19.15-20.00 Keynote lecture, John Hardy

Cocktail reception will follow at the Hotel for all participants

SECOND DAY
Saturday, September 9, 2017

8.30-9.45 Dementia with Lewy Bodies
Chairs: Ian McKeith and Philipp Kahle
The evolving spectrum of DLB, Ian McKeith
The genetics of DLB, John Hardy
DLB neuropathology, Glenda Halliday
Biomarkers in DLB, Elizabeth Kapaki
Animal models of DLB: Philipp Kahle

09.45-10.45 REM Sleep Behavior Disorder
Chairs: Eduardo Tolosa and Wolfgang Oertel
Longitudinal follow-up of patients with RBD, Eduardo Tolosa
Polysomnography in the diagnosis of RBD, Anastasios Bonakis
Multimodal phenotyping of RBD, Wolfgang Oertel
The RBD PPMI prodromal cohort: Kuldip Dave

10.45-11.15 ROUND TABLE DISCUSSION of DLB and RBD
Chairs: Ian McKeith and Eduardo Tolosa

11.15-11.45 COFFEE BREAK

11.45-13.00 Multiple System Atrophy
Chairs: Gregor Wenning, Poul Henning-Jensen
The natural history of MSA, Gregor Wenning
Pitfalls in MSA diagnosis, Maria Stamelou
MSA neuropathology, Janice Holton
Cellular models of MSA, Poul Henning Jensen
Experimental therapeutics in MSA mouse models, Nadia Stefanova

13.00-13.30 ROUND TABLE DISCUSSION of MSA

13.30-14.30 LUNCH

14.30-15.45 NEUROBIOLOGY OF ALPHA-SYNUCLEIN I: Protein Homeostasis
Chairs: Katerina Paleologou and George Tofaris
Alpha-synuclein in the MAM, Serge Przedborski
Ligase-dependent regulation of alpha-synuclein, George Tofaris
Autophagy and alpha-synuclein, Maria Xilouri
Inter-connection between GCase and alpha-synuclein through the lysosome, Michael Schlossmacher
Regulation of alpha-synuclein extracellular clearance, Kostas Vekrellis

15.45-16.45 NEUROBIOLOGY OF ALPHA-SYNUCLEIN II: Protein Aggregation
Chairs: Glenda Halliday, Hilal Lashuel
Biophysical properties of alpha-synuclein, Markus Zweckstetter
Forms of alpha-synuclein aggregates, Ronald Melki
Post-Translational modifications in alpha-synucelin as modifiers of toxicity and aggregation, Tiago Outeiro
Advancing our understanding of Alpha Synuclein functions in health and disease through embracing the complexity of its proteoforms: Hilal Lashuel

16.45-17.15 ROUND TABLE DISCUSSION: Protein aggregation and homeostasis
Chairs: Hilal Lashuel and George Tofaris

17.15-18.00 COFFEE BREAK

18.00-19.30 NEUROBIOLOGY OF ALPHA-SYNUCLEIN III: Transmission
Chairs: Kostas Vekrellis and Serge Przedborski
The origin of extracellular alpha-synuclein, Evangelia Emmanouilidou
Inter-relationship of spreading to inflammation and lysosomal function, Seung-Jae Lee
Systemic transmission of alpha-synuclein strains, Veerle Baekelandt
Insights into alpha-synuclein transmission through viral models, Donato di Monte
Propagation models using synucleinopathy neuropathological material, Erwan Bezard
Are human neuropathological data consistent with the transmission hypothesis?, Glenda Halliday

19.30-20.00 ROUND TABLE DISCUSSION: Alpha-synuclein transmission

20.00-20.50 KEYNOTE ADDRESS II: The legacy of Lewy Bodies
Chair: Glenda Halliday
20.00-20.05 Introduction, Glenda Halliday
20.05-20.50 Keynote Lecture
Maria-Grazia Spillantini

21.00 FACULTY DINNER

THIRD DAY
Sunday, September 10, 2017

8.45-9.40 Poster Awards – Oral Presentations OF The Best Posters
Chairs: PierFranco Spano, Kostas Vekrellis

P51
AUTOPHAGY PROMOTES ALPHA-SYNUCLEIN RELEASE AND TRANSFER VIA EXTRACELLULAR VESICLES WITH A HYBRID AUTOPHAGO/EXOSOME-LIKE PHENOTYPE
Georgia Minakaki1, Agnes Kittel2, Stefanie Menges1, Evangelia Emmanouilidou3, Iris Schaeffner4, Katalin Barkovits5, Anna Bergmann1, E. Rockenstein7, A. Adame6, F. Marxreiter1, Brit Mollenhauer7, D. Galasko6, Edit Irιn Buzαs8, Ursula Schlφtzer-Schrehardt9, Katrin Marcus5, Wei Xiang4, D.C. Lie4, K. Vekrellis3, E. Masliah6,10, J. Winkler1, J. Klucken1 1Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander- University Erlangen-Nurnberg (FAU), Erlangen, Germany, 2Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary, 3Department of Neuroscience, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, 4Institute of Biochemistry, FAU, Erlangen, Germany, 5Medizinisches Proteom-Center, Medical Faculty, Ruhr University Bochum, Bochum, Germany, 6Department of Neurosciences University of California, CA San Diego, USA, 7Paracelsus-Elena-Klinik, Kassel and Departments of Neuropathology & Neurosurgery, & University Medical Center, Gottingen, 8Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary, 9Department of Opthalmology University Hospital Erlangen, FAU, Erlangen, Germany, 10Department of Pathology, University of California, CA San Diego, USA

P55
Modeling the differential regulation of SNCA expression using isogenic iPSC-derived neurons : implication to the heterogeneity of synucleinopathies
Lidia Tagliafierro1,2, Madison E. Zamora1,2, Haylee Bergstrom1,2, Ornit Chiba-Falek1,2 1Department of Neurology, Duke University Medical Center, Durham, NC, USA, 2Center for Genomic and Computational Biology, Duke University Medical Center, Durham, NC, USA

P61
MODULATION OF BETA-GLUCOCEREBROSIDASE INCREASES ΑLPHA-SYNUCLEIN SECRETION AND EXOSOME RELEASE IN A MOUSE MODEL OF PARKINSON’S DISEASE
V. Papadopoulos1, Georgia Nikolopoulou1, Antonia Karachaliou1, Ivi Antoniadou1, Giovanna Arianoglou1, Evangelia Emmanouilidou1, L. Stefanis2, P. Sardi3, K. Vekrellis1 1Division of Basic Neurosciences, Biomedical Research Foundation, Academy of Athens, Athens, Greece, 2Division of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece, 3Sanofi Genzyme, Framingham, MA, USA

P63
INVESTIGATING INFLAMMATORY RESPONSES IN A NOVEL RAT MODEL OF G51D α-SYNUCLEIN FAMILIAL PARKINSON’S DISEASE
S. West1, K. Dolt1, Claire Davies2, Veronique Miron2, T. Kunath1 1MRC Centre for Regenerative Medicine, The University of Edinburgh, UK, 2MRC Centre for Reproductive Health, QMRI, The University of Edinburgh, UK

P77
NOVEL VIRAL-VECTOR MEDIATED NONHUMAN PRIMATE MODEL OF MULTIPLE SYSTEM ATROPHY
D.J. Marmion1, Mari Savolainen1, R.J. Mandel2, D. Kirik3, Y. Chu1, T.J. McCown4,5, S.J. Gray4,6, J.H. Kordower1,7 1Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 2Department of Neuroscience, University of Florida, Gainesville, FL, 3Department of Experimental Medical Science, Lund University, Lund, Sweden, 4Gene Therapy Center, Chapel Hill, NC, 5Department of Psychiatry, University of North Carolina, Chapel Hill, NC, 6 Department of Ophthalmology, Chapel Hill, NC, 7The Van Andel Institute, Grand Rapids, MI, USA

P82
LONG TERM EFFECTS OF ALPHA-SYNUCLEINOPATHY PROPAGATED FROM THE OLFACTORY BULB
Nolwen Rey1, Sonia George1, Jennifer Steiner1, Z. Madaj2, K. Luk3, J. Trojanowski3, Virginia Lee3, P. Brundin1 1Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA, 2Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, MI, USA, 3Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA, USA

09.40-10.00 Special Lecture A receptor for alpha-synuclein transmission, Ted Dawson

10.00-11.30 Experimental Therapeutics
Chairs: Eliezer Masliah, Maria Grazia Spillantini
Active immunization therapeutics in synucleinopathy animal models, Eliezer Masliah
Alpha-synuclein antibodies as therapeutics in synucleinopathies – Focus on mechanism of action, Karina Fog
Small molecules as therapeutics in synucleinopathies, Armin Giese
Imaging and other outcomes in translational studies in synucleinopathy animal models, Deniz Kirik

11.30-12.00 COFFEE BREAK

12.00-14.00 Treatments in the Clinic
Chairs: Wolfgang Oertel, Eliezer Masliah
MSA Clinical Trials, Gregor Wenning
The prospect of imaging outcomes in clinical trials, David Brooks
ROUND TABLE DISCUSSION
Experimental therapeutics and Clinical Trials Experimental therapeutics and Clinical Trials. With company representatives from: UCB, Pierandrea Muglia Abbvie, Maurizio F. Facheris Affiris, Alexandra Kutzelnigg Biogen, Jesse Cedarbaum Prothena, Wagner Zago Bioarctic, Lars Lannfelt

14.00-14.10 Meeting wrap-up
Chairs: Kostas Vekrellis, Leonidas Stefanis